Glatiramer acetate does not protect from acute ischemic stroke in mice

Area of Science:

• Neuroscience
• Immunology
• Neurology

Background:

• The immune system's role in acute ischemic stroke pathophysiology is recognized, yet targeted immunomodulatory treatments are absent.
• Glatiramer acetate, an approved immunomodulator for multiple sclerosis, shows potential for other neuroinflammatory conditions.
• This study investigates glatiramer acetate's efficacy in a preclinical model of stroke.

Purpose of the Study:

• To evaluate the neuroprotective effects of glatiramer acetate in a mouse model of ischemic stroke.
• To determine if glatiramer acetate reduces infarct volume and improves functional recovery after middle cerebral artery occlusion.

Main Methods:

• Transient middle cerebral artery occlusion (60 minutes) was induced in male C57Bl/6 mice.
• Mice received glatiramer acetate (3.5 mg/kg) 30 minutes before stroke induction.
• Lesion volumes and functional outcomes were assessed on day 1 post-stroke.

Main Results:

• Glatiramer acetate pretreatment did not significantly reduce lesion volumes.
• No improvement in functional outcomes was observed on day 1 after stroke.
• The drug failed to demonstrate efficacy in this acute ischemic stroke model.

Conclusions:

• Glatiramer acetate did not provide protection against acute ischemic stroke in this experimental setting.
• Further investigation is required to ascertain the therapeutic potential of glatiramer acetate and similar immunomodulators in brain ischemia.